116 related articles for article (PubMed ID: 25723504)
1. Considering autotaxin inhibitors in terms of 2D-QSAR and 3D-mapping- review and evaluation.
Katsamakas S; Bermperoglou E; Hadjipavlou-Litina D
Curr Med Chem; 2015; 22(12):1428-61. PubMed ID: 25723504
[TBL] [Abstract][Full Text] [Related]
2. Structural Basis for Inhibition of Human Autotaxin by Four Potent Compounds with Distinct Modes of Binding.
Stein AJ; Bain G; Prodanovich P; Santini AM; Darlington J; Stelzer NM; Sidhu RS; Schaub J; Goulet L; Lonergan D; Calderon I; Evans JF; Hutchinson JH
Mol Pharmacol; 2015 Dec; 88(6):982-92. PubMed ID: 26371182
[TBL] [Abstract][Full Text] [Related]
3. Discovery and synthetic optimization of a novel scaffold for hydrophobic tunnel-targeted autotaxin inhibition.
Ragle LE; Palanisamy DJ; Joe MJ; Stein RS; Norman DD; Tigyi G; Baker DL; Parrill AL
Bioorg Med Chem; 2016 Oct; 24(19):4660-4674. PubMed ID: 27544588
[TBL] [Abstract][Full Text] [Related]
4. Autotaxin inhibition: development and application of computational tools to identify site-selective lead compounds.
Norman DD; Ibezim A; Scott WE; White S; Parrill AL; Baker DL
Bioorg Med Chem; 2013 Sep; 21(17):5548-60. PubMed ID: 23816044
[TBL] [Abstract][Full Text] [Related]
5. Structure-based discovery of (S)-2-amino-6-(4-fluorobenzyl)-5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6]pyrido[3,4-b]indole-1,3(2H)-dione as low nanomolar, orally bioavailable autotaxin inhibitor.
Roy A; Sarkar T; Datta S; Maiti A; Chakrabarti M; Mondal T; Mondal C; Banerjee A; Roy S; Mukherjee S; Muley P; Chakraborty S; Banerjee M; Kundu M; Roy KK
Chem Biol Drug Des; 2022 Mar; 99(3):496-503. PubMed ID: 34951520
[TBL] [Abstract][Full Text] [Related]
6. Screening and X-ray crystal structure-based optimization of autotaxin (ENPP2) inhibitors, using a newly developed fluorescence probe.
Kawaguchi M; Okabe T; Okudaira S; Nishimasu H; Ishitani R; Kojima H; Nureki O; Aoki J; Nagano T
ACS Chem Biol; 2013 Aug; 8(8):1713-21. PubMed ID: 23688339
[TBL] [Abstract][Full Text] [Related]
7. Computer Aided Drug Design Approaches for Identification of Novel Autotaxin (ATX) Inhibitors.
Vrontaki E; Melagraki G; Kaffe E; Mavromoustakos T; Kokotos G; Aidinis V; Afantitis A
Curr Med Chem; 2016; 23(17):1708-24. PubMed ID: 26997151
[TBL] [Abstract][Full Text] [Related]
8. Autotaxin inhibitors: a patent review.
Barbayianni E; Magrioti V; Moutevelis-Minakakis P; Kokotos G
Expert Opin Ther Pat; 2013 Sep; 23(9):1123-32. PubMed ID: 23641951
[TBL] [Abstract][Full Text] [Related]
9. Development and therapeutic potential of autotaxin small molecule inhibitors: From bench to advanced clinical trials.
Matralis AN; Afantitis A; Aidinis V
Med Res Rev; 2019 May; 39(3):976-1013. PubMed ID: 30462853
[TBL] [Abstract][Full Text] [Related]
10. Structure-Activity Relationships of Small Molecule Autotaxin Inhibitors with a Discrete Binding Mode.
Miller LM; Keune WJ; Castagna D; Young LC; Duffy EL; Potjewyd F; Salgado-Polo F; Engel García P; Semaan D; Pritchard JM; Perrakis A; Macdonald SJ; Jamieson C; Watson AJ
J Med Chem; 2017 Jan; 60(2):722-748. PubMed ID: 27982588
[TBL] [Abstract][Full Text] [Related]
11. Discovery of Novel Indole-Based Allosteric Highly Potent ATX Inhibitors with Great
Lei H; Guo M; Li X; Jia F; Li C; Yang Y; Cao M; Jiang N; Ma E; Zhai X
J Med Chem; 2020 Jul; 63(13):7326-7346. PubMed ID: 32479084
[TBL] [Abstract][Full Text] [Related]
12. Structure-Based Discovery of Novel Chemical Classes of Autotaxin Inhibitors.
Magkrioti C; Kaffe E; Stylianaki EA; Sidahmet C; Melagraki G; Afantitis A; Matralis AN; Aidinis V
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32977539
[TBL] [Abstract][Full Text] [Related]
13. Discovery and optimization of ATX inhibitors via modeling, synthesis and biological evaluation.
Balupuri A; Lee MH; Chae S; Jung E; Yoon W; Kim Y; Son SJ; Ryu J; Kang DH; Yang YJ; You JN; Kwon H; Jeong JW; Koo TS; Lee DY; Kang NS
Eur J Med Chem; 2018 Mar; 148():397-409. PubMed ID: 29477073
[TBL] [Abstract][Full Text] [Related]
14. Autotaxin inhibitors: a patent review (2012-2016).
Nikolaou A; Kokotou MG; Limnios D; Psarra A; Kokotos G
Expert Opin Ther Pat; 2017 Jul; 27(7):815-829. PubMed ID: 28447479
[TBL] [Abstract][Full Text] [Related]
15. Stepwise development of structure-activity relationship of diverse PARP-1 inhibitors through comparative and validated in silico modeling techniques and molecular dynamics simulation.
Halder AK; Saha A; Saha KD; Jha T
J Biomol Struct Dyn; 2015; 33(8):1756-79. PubMed ID: 25350685
[TBL] [Abstract][Full Text] [Related]
16. A 3D view of autotaxin.
Nishimasu H; Ishitani R; Aoki J; Nureki O
Trends Pharmacol Sci; 2012 Mar; 33(3):138-45. PubMed ID: 22277299
[TBL] [Abstract][Full Text] [Related]
17. Virtual screening approaches for the identification of non-lipid autotaxin inhibitors.
Parrill AL; Echols U; Nguyen T; Pham TC; Hoeglund A; Baker DL
Bioorg Med Chem; 2008 Feb; 16(4):1784-95. PubMed ID: 18036821
[TBL] [Abstract][Full Text] [Related]
18. Optimization of a pipemidic acid autotaxin inhibitor.
Hoeglund AB; Bostic HE; Howard AL; Wanjala IW; Best MD; Baker DL; Parrill AL
J Med Chem; 2010 Feb; 53(3):1056-66. PubMed ID: 20041668
[TBL] [Abstract][Full Text] [Related]
19. Steroid binding to Autotaxin links bile salts and lysophosphatidic acid signalling.
Keune WJ; Hausmann J; Bolier R; Tolenaars D; Kremer A; Heidebrecht T; Joosten RP; Sunkara M; Morris AJ; Matas-Rico E; Moolenaar WH; Oude Elferink RP; Perrakis A
Nat Commun; 2016 Apr; 7():11248. PubMed ID: 27075612
[TBL] [Abstract][Full Text] [Related]
20. Autotaxin--an LPA producing enzyme with diverse functions.
Nakanaga K; Hama K; Aoki J
J Biochem; 2010 Jul; 148(1):13-24. PubMed ID: 20495010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
